Reply  by Paraskevas, Kosmas I. et al.
LETTERS TO THE EDITOR
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sRegarding “Optimal statin type and dosage for
vascular patients”
Paraskevas et al1 are claiming that rosuvastatin or atorvastatin
is the optimal statin at a dose of 20 mg/d for vascular patients.
Epidemiologic studies showed that a low level of high-density
lipoprotein cholesterol (HDL-C; 1.0 mmol/L or 40 mg/dL),
independent of low-density lipoprotein cholesterol (LDL-C), is a
marker of cardiovascular risk.2 Despite the known efficacy of the
various statins to increase HDL-C, the interindividual response is
rather high and unpredictable. Therefore, the optimal HDL-C–
elevating statin in a particular patient cannot be predicted.
The authors state that statin-induced adverse events may be
dose-related, which is substantiated by large trials. However, it is
well known that these studies underestimate side effects, partly
because the exclusion criteria avoid to a large extent possible drug
interactions. Especially side effects, such as mild myopathies, have
not been specifically questioned and documented. No data from
comparative trial investigating muscular side effects are available
yet.
In 1000 patients admitted to our lipid unit because of side
effects, the prevalence of myopathy exactly reflected the frequency
that the respective statins were prescribed at that time (Table).3 A
creatine kinase increase (5-fold) on statin monotherapy was
extremely rare (16 of 1111 patients). Therefore, there is no evi-
dence that atorvastatin is associated with the highest and fluvastatin
with the lowest risk of adverse events.
The assumption that milder side effects of certain statins are
counterbalanced by their lower efficacy is not evidence-based.
With the option of a weekly dosing of a long half-life statin for
statin-intolerant patients, the authors contradict their own asser-
tion that only the most potent statins at20mg/d are appropriate
for vascular patients. Furthermore, statin-intolerant patients who
do not tolerate any lipid-lowering agent, even on alternate-day
dosing, should therefore undergo LDL apheresis, according to the
respective national guidelines.
In our unit in 50% of patients with clinically symptomatic
and proven atherosclerosis, other statins than rosuvastatin and
atorvastatin are effective to achieve target values according to the
guidelines. A 40% decrease in LDL-C has been described as
being necessary to induce regression of atherosclerosis.4 A long-
term lesion stabilization achieved by LDL-lowering to target val-
ues may be sufficient. What is the clinical proof concerning the
cardiovascular event rate for the 40% LDL-lowering? Interindi-
vidual response to various statins varies considerably, not allowing
preferential recommendations.
Moreover, statins have pleiotropic effects, independent of
changes in serum cholesterol, not considered by Paraskevas et al,1
including improving endothelial function, exerting anti-inflamma-
Table. The prevalence of myopathy exactly reflected the
frequency that the respective statin was prescribeda
Statin Patients no. (%) Myopathies (%)
Patient total 1111
Simvastatin 400 (36.01) 34.80
Atorvastatin 396 (35.64) 37.20
Fluvastatin 156 (14.04) 14.00
Pravastatin 111 (9.99) 11.80
Lovastatin 41 (3.69) 0.70
Rosuvastatin 7 (0.63) 1.50o
paUnpublished data.
928ory actions, and stabilizing atherosclerotic plaques.5 Furthermore,
o statement on combination treatment, which would also allow
chieving the goal with other statins, is given.
In some patients, extremely elevated lipoprotein(a) (100
g/dL), cigarette smoking, or other risk factors despite normal
ipids, are the key pathogenetic mechanisms for the development
f vascular disease. These patients do not fit into the therapeutic
ecommendations at all.
We agree with a key statement that adherence to statin therapy
s the central problem to be addressed in this group of patients.
owever, we do not believe that this simple statin type and dose
ecommendation for vascular disease patients is justified at present.
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Berent and Sinzinger1 raise many, mostly questionable points.
irst, regarding their comment that a low level of high-density
ipoprotein cholesterol (HDL-C) is a marker of cardiovascular risk
ndependent of low-density lipoprotein cholesterol (LDL-C) lev-
ls, a recent systematic review and meta-regression analysis of 108
tudies, including 299,310 participants, showed that by increasing
DL-C levels, there is no reduction in the risk of coronary heart
isease events, coronary heart disease deaths, or total deaths.2 This
eta-analysis concluded that a reduction in LDL-C levels should
e the primary goal for lipid-modifying interventions.2
Second, the response of patients varies with all drugs; we
uggested statin types and dosages that are more likely to achieve
uideline targets.3 There will also always be variations in statin use.
urely, Berent and Sinzinger do not advocate a random choice of
tatin types and dosages.
Third, they question the statement that statin-induced “my-
pathy” is dose-related and mention that “especially side effects,
uch as mild myopathies, have not been specifically questioned and
ocumented.”1 The authors seem not to be aware of a study
ublished last year, the Study of the Effectiveness of Additional
eductions in Cholesterol and Homocysteine (SEARCH). This
tudy, comprising 12,064 participants, showed that the incidence
f myopathy was 30-fold greater in patients taking 80 mg com-
ared with 20 mg of simvastatin.4
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Volume 54, Number 3 Letters to the Editor 929Fourth, the Table presented by Berent and Sinzinger contains
several errors that affect its validity. It is therefore not surprising
that these data are unpublished. In the text, they mention that, “In
1000 patients admitted to our lipid unit because of side effects,
the prevalence of myopathy exactly reflected the frequency the
respective statins were prescribed at that time.”1 Then, in the Table
they say, “The prevalence of myopathy exactly reflected the fre-
quency that the respective statin was prescribed.” Do the authors
mean that all 1111 patients had myopathy and no other side
effects? Or is the percentage given the actual percentage of patients
presenting with myopathy? If this is so, what is 1.5% of the seven
patients taking rosuvastatin? Is it 0.1 patients? There are also
several other problems: For example, seven patients were taking
rosuvastatin among 1111 statin users (0.63% of the study popula-
tion), and 41 patients (69% of the study population, almost six
times more) were taking lovastatin. If the incidence of myopathy is
less than half in a sixfold bigger group (0.70% vs 1.50% for
rosuvastatin vs lovastatin, respectively), then the prevalence of
myopathy is not “exactly reflecting” the frequency of the respective
statin that was prescribed!1 Statin-induced myopathy should be
viewed in the context of the literature, including our review,3 and
not a small sample reflecting local practice and opinion.
Fifth, Berent and Sinzinger disagree with us and mention that
“there is no evidence that atorvastatin is associated with the highest
and fluvastatin with the lowest risk of adverse events.”1 This is
inconsistent with the reference5 originally cited in our review,3
which is a meta-analysis of 18 trials that included 71,108 patients
and 301,374 person-years of follow-up. One of the conclusions of
this meta-analysis was that “atorvastatin is associated with the
greatest risk of adverse events and fluvastatin with the least risk.”5
Sixth, there are obvious limitations with LDL-C apheresis for
statin intolerance, such as availability and the considerable cost.
Seventh, Berent and Sinzinger ask, “what is the clinical proof
concerning the cardiovascular event rate for the 40% LDL-
lowering?” The clear answer is provided in the Results section of
our article.
Eighth, they go on, saying that, “statins have pleiotropic
effects, independent of changes in serum cholesterol levels, not
considered by Paraskevas et al . . . .”1 There is a section in our
review (“Statins and vascular diseases”) with three subsections
(“Statins and AAAs,” “Statins and carotid artery disease,” and
“Statins and PAD”) in which the pleiotropic effects of statins in
vascular patients are discussed.
Ninth, they support that, “Furthermore, no statement on
combination treatment, which would also allow achieving the goal
with other statins, is given.”1 Again, Berent and Sinzinger ignore dur article’s section on “Options for statin intolerant patients,” as
ell as the references cited in this section.
Tenth, their comment about lipoprotein(a), smoking, and
ther risk factors is rather confusing. Essentially, the higher the
erceived overall vascular risk (whatever the contributing factors),
he greater the need for aggressive LDL-C lowering.
We appreciate the interest in our review.
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